Item 2. PROPERTIES
4K characters. Original on sec.gov · Markdown
Item 2. PROPERTIES
The Company's corporate headquarters are located in Burlington, North Carolina, and include facilities that are both owned and leased.
Labcorp Diagnostics (Dx) operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The table below summarizes certain information as to Dx's principal operating and administrative facilities as of December 31, 2020.
| Location | Nature of Occupancy | ||||
| Primary Facilities: | |||||
| Birmingham, Alabama | Leased | ||||
| Phoenix, Arizona | Owned | ||||
| Los Angeles, California | Leased | ||||
| Monrovia, California | Leased | ||||
| San Diego, California | Leased | ||||
| San Francisco, California | Leased | ||||
| Shelton, Connecticut | Leased | ||||
| Tampa, Florida | Leased | ||||
| Westborough, Massachusetts | Leased | ||||
| St. Paul, Minnesota | Owned | ||||
| Raritan, New Jersey | Owned | ||||
| Burlington, North Carolina (5) | Owned/Leased | ||||
| Research Triangle Park, North Carolina (3) | Leased | ||||
| Dublin, Ohio | Owned | ||||
| Brentwood, Tennessee | Leased | ||||
| Dallas, Texas | Leased | ||||
| Houston, Texas | Leased | ||||
| Herndon, Virginia | Leased | ||||
| Seattle, Washington | Leased | ||||
| Spokane, Washington (3) | Leased |
Labcorp Drug Development (DD) operates on a global scale. The table below summarizes certain information as to DD's principal operating and administrative facilities as of December 31, 2020.
| Location | Nature of Occupancy | ||||
| Primary Facilities: | |||||
| Mechelen, Belgium | Leased | ||||
| Beijing, China | Leased | ||||
| Shanghai, China (2) | Owned/Leased | ||||
| Muenster, Germany | Owned | ||||
| Pune, India | Leased | ||||
| Bangalore, India | Leased | ||||
| Singapore | Leased | ||||
| Geneva, Switzerland | Owned | ||||
| Eye, United Kingdom | Owned | ||||
| Harrogate, United Kingdom | Owned | ||||
| Huntingdon, United Kingdom | Owned | ||||
| Leeds, United Kingdom | Owned | ||||
| Maidenhead, United Kingdom | Leased | ||||
| Shardlow, United Kingdom | Owned | ||||
| York, United Kingdom | Leased | ||||
| San Francisco, California | Leased | ||||
| Daytona Beach, Florida | Leased | ||||
| Greenfield, Indiana | Owned | ||||
| Indianapolis, Indiana | Leased | ||||
| Gaithersburg, Maryland | Leased | ||||
| Ann Arbor, Michigan | Leased | ||||
| Minneapolis, Minnesota | Leased | ||||
| Princeton, New Jersey | Leased | ||||
| Somerset, New Jersey | Owned | ||||
| Dallas, Texas | Leased | ||||
| Chantilly, Virginia | Leased | ||||
| Madison, Wisconsin | Owned |
All of the Company’s primary laboratory and drug development facilities have been built or improved for the purpose of providing commercial laboratory testing or drug development services. The Company believes that these existing facilities and plans for expansion are suitable and adequate and will provide sufficient production capacity for the Company's currently foreseeable level of operations. The Company believes that if it were unable to renew a lease or if a lease were to be terminated on any of the facilities it presently leases, it could find alternate space at competitive market rates and readily relocate its operations to such new locations without material disruption to its operations.
Previous: Item 1B. UNRESOLVED STAFF COMMENTS · Next: Item 3. LEGAL PROCEEDINGS